<DOC>
	<DOCNO>NCT00162981</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy clobazam adjunctive therapy treatment seizure lead drop attack ( drop seizure ) subject 2 30 year age Lennox-Gastaut Syndrome ( LGS ) . Subjects enrol approximately 10 investigational site U.S. 15 week . Subjects randomly assign either low dose high dose . The study include baseline period , titration period maintenance period . After maintenance period , subject either continue open-label extension study enter taper period final visit 1 week last dose .</brief_summary>
	<brief_title>Clobazam Subjects With Lennox-Gastaut Syndrome</brief_title>
	<detailed_description>LGS pose significant treatment challenge . While antiepileptic medication mainstay treatment , one antiepileptic drug ( AED ) provide satisfactory relief patient LGS combination treatment often require . Many patient LGS refractory standard AED treatment . More effective well tolerate treatment option need population medically intractable epilepsy patient . Clobazam unique non-1 , 4-benzodiazepine use treatment epilepsy .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lennox Gastaut Syndrome</mesh_term>
	<mesh_term>Epilepsy , Generalized</mesh_term>
	<mesh_term>Clobazam</mesh_term>
	<criteria>Key Subject must &lt; 11 year age onset LGS Subject must LGS Subject must least 1 stable dose AED Parent caregiver must able keep accurate seizure diary Key Etiology subject 's seizure progressive neurologic disease . Subjects tuberous sclerosis exclude study participation Subject episode status epilepticus within 12 week baseline Subject anoxic episode require resuscitation within 1 year screen Subject clinically significant history allergic reaction significant sensitivity benzodiazepine Subject take 3 concurrent AEDs . Note : Vagal Nerve Stimulation ( VNS ) ketogenic diet allow count one three allow AEDs If subject ketogenic diet , less 4 week prior screen suffers frequent stool If subject VNS , settings stable least 4 week prior screen Subject take corticotropins 6 month prior screen Subject currently take longterm systemic steroid ( exclude inhale medication asthma treatment ) daily medication know exacerbate epilepsy . An exception make prophylactic medication , example , urinary tract infection asthma If subject take felbamate , take less 1 year prior screen previous treatment felbamate result withdrawal due liver bone marrow adverse event</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>